Post-earnings recap
Reported
Tue, Aug 8, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
Protagonist Therapeutics reported a loss per share of $0.89, but the stock still rose by 1.12%. Investors may be reacting positively to the company's focus on clinical development despite the lack of revenue information. The absence of guidance leaves some uncertainty about future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.89 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management did not offer detailed commentary on the quarter's performance. They emphasized their commitment to ongoing clinical development.
Management did not provide specific revenue figures for the quarter.
The company remains focused on advancing its clinical programs.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—